Cancer in Latvia

IARC estimates 11,317 new cancer cases and 5,803 cancer deaths in Latvia in 2024; the commonest new cancers are prostate, breast and colorectum. This page is assembled automatically from OnCo's data: 34 trials with a site there, 2 institutions and 3 people, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

11,317

all cancers

Deaths

5,803

all cancers

Incidence rate

282.2

per 100,000, age-standardised

Mortality rate

116.6

per 100,000, age-standardised

Cumulative risk

28.4%

of a cancer by age 74

Population

1,871,876

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Prostate	1,715	102.3	Prostate cancer
Breast	1,302	67.9	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Colorectum	1,130	23.7	Colorectal cancer
Trachea, bronchus and lung	1,030	22.8	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Kidney	542	14.3	Renal cell carcinoma
Bladder	507	10.2	Bladder & urothelial cancer
Stomach	484	11.0	Gastric & gastro-oesophageal junction cancer
Pancreas	450	9.3	Pancreatic ductal adenocarcinoma
Corpus uteri	391	15.9	Endometrial cancer
Leukaemia	290	7.6	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	916	19.9	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	647	11.4	Colorectal cancer
Prostate	476	21.8	Prostate cancer
Breast	427	15.2	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Pancreas	413	7.8	Pancreatic ductal adenocarcinoma
Stomach	358	7.5	Gastric & gastro-oesophageal junction cancer
Bladder	210	3.5	Bladder & urothelial cancer
Kidney	192	3.4	Renal cell carcinoma
Liver and intrahepatic bile ducts	182	4.1	Hepatocellular carcinoma
Ovary	173	6.9	Ovarian cancer

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Latvia”, in Northern Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

34 trials in OnCo · 6 recruiting overall

34 trials

Trial			Lead sponsor
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650	Phase 3	Recruiting	Merck Sharp & Dohme LLC	330	2026-10-06
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment NCT07472517	Phase 3	Recruiting	Boehringer Ingelheim	245	2026-09-29
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi NCT05920356	Phase 3	Recruiting	Amgen	420	2026-09-25
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer NCT06774131	Phase 3	Recruiting	UroGen Pharma Ltd.	79	2026-09-03
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC NCT05491525	Phase 2/3	Recruiting	Urovant Sciences GmbH	38	2026-06-15
ARANOTE NCT04736199	Phase 3	Completed	Bayer	131	2026-09-29
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer NCT06331299	Phase 3	Active not recruiting	UroGen Pharma Ltd.	48	2026-09-28
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer ( NCT06077760	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	229	2026-09-18
KEYNOTE-671 NCT03425643	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	227	2026-07-29
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer NCT04464226	Phase 3	Active not recruiting	Bayer	335	2026-07-07
lidERA NCT04961996	Phase 3	Active not recruiting	Hoffmann-La Roche	622	2026-06-17
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) NCT06593522	Phase 2	Active not recruiting	Amgen	91	2026-05-28
FORTITUDE-101 NCT05052801	Phase 3	Completed	Amgen	300	2026-05-27
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) NCT04380636	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	205	2026-05-15
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer NCT05243550	Phase 3	Active not recruiting	UroGen Pharma Ltd.	65	2026-05-11
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) NCT04241185	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	134	2026-05-01
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy NCT06726265	Phase 3	Active not recruiting	Immutep S.A.S.	147	2026-03-18
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage NCT05353257	Phase 3	Active not recruiting	Shanghai Henlius Biotech	129	2026-01-13
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) NCT05609968	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	180	2025-12-24
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. NCT03869892	Phase 3	Active not recruiting	Institut de Recherches Internationales Servier	190	2025-12-22
CUPISCO NCT03498521	Phase 2	Completed	Hoffmann-La Roche	125	2025-11-19
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer NCT03390686	Phase 3	Active not recruiting	Prestige Biopharma Limited	18	2025-05-31
BROCADE3 NCT02163694	Phase 3	Completed	AbbVie	219	2025-02-19
IMpassion130 NCT02425891	Phase 3	Completed	Hoffmann-La Roche	247	2022-07-19
ARAMIS NCT02200614	Phase 3	Completed	Bayer	404	2022-06-28
IMpower150 NCT02366143	Phase 3	Completed	Hoffmann-La Roche	240	2021-09-23
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) NCT03033511	Phase 3	Terminated	AbbVie	308	2021-07-29
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) NCT03061812	Phase 3	Completed	AbbVie	195	2021-02-23
HALO 109-301 NCT02715804	Phase 3	Terminated	Halozyme Therapeutics	217	2020-07-14

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Latvia, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Latvia is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

2 institutions

Pauls Stradiņš Clinical University Hospital Riga East University Hospital / Oncology Centre of Latvia

3 people

People whose main affiliation in OnCo is an institution or company in Latvia.

Alinta Hegmane Lauris Vidzis Vadims Beļuns

Approvals

Latvia is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Latvia's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Latvia, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Latvia's own sources.

Latvia is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/lv.json; every country: /api/v1/countries.json.